



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

## Operations Office

---

Date: April 24, 2009  
To: Primary Clinical Research Associates  
From: Lynn Flickinger  
Re: N083E, Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer

The attached Nadir/Adverse Event Form has been revised as follows:

- On the first page
  - The 2nd question was removed - this was an error.
  - A reference to WBC was changed to Hgb for the first test (Platelets) as WBC is not being collected.

If you have any questions, please contact Lynn Flickinger ([flickinger.lynn@mayo.edu](mailto:flickinger.lynn@mayo.edu) or telephone at 507-538-7035).

Attachments